Hematopoietic stem cell transplant (HSCT) recipients are at risk for Epstein-Barr virus (EBV)-associated, post transplant lymphoproliferative disorder (PTLD). Studies have suggested that early treatment may improve the outcome of patients with PTLD. Thus, significant attention has been focused on PCR-based approaches for preemptive (i.e., prior to clinical presentation) diagnosis. Reports from several transplant centers have demonstrated that HSCT recipients with PTLD generally have higher concentrations of EBV DNA in the peripheral blood than patients without PTLD. However, the PCR values of patients with PTLD typically span multiple orders of magnitude and overlap significantly with values from patients without PTLD. Thus, questions remain about the sensitivity and predictive value of these assays. Preemptive strategies using rituximab and/or EBVspecific cytotoxic T lymphocytes have been evaluated in patients with elevated EBV viral loads. We review the current literature, discuss our institutional experience and identify several areas of future research that could improve the diagnosis and treatment of this life-threatening disorder in HSCT recipients.
proliferative disorder; rituximab; stem cell transplant; PCR Infection by Epstein-Barr virus (EBV), a ubiquitous g-herpesvirus, occurs in over 90% of the world's population. [1] [2] [3] Healthy individuals mount a profound immune response to EBV infection. While antibodies effectively neutralize virus infectivity, CD4 þ and CD8 þ T cells control the proliferation of primary and latent EBV-infected cells.
EBV is associated with a spectrum of clinical presentations in hematopoietic stem cell transplant (HSCT) recipients, from fever to post transplant lymphoproliferative disorder (PTLD), which arise from the outgrowth of latently infected B cells in the absence of competent immune surveillance by cytotoxic T cells.
PTLDs are extremely heterogeneous, ranging from polyclonal hyperplasia to aggressive, non-Hodgkin's lymphoma. [1] [2] [3] Thus, PTLD can present with a diverse spectrum of clinical symptoms and signs, most notably a sepsis-like syndrome with rapidly progressive lymphoma or a mononucleosis-like illness with fever, enlarged tonsils and/or cervical lymphadenopathy. PTLD may involve virtually any organ system, including the central nervous system, bone marrow, intestine and lungs. The overall frequency of PTLD after allogeneic HSCT is approximately 1%. The highest incidence occurs in the first 6 months after transplant, and the vast majority of cases develop during the first year. 4 
Risk factors for PTLD
Multiple published studies [4] [5] [6] [7] [8] [9] [10] have identified predisposing factors for PTLD, including in vivo and in vitro T-cell depletion. In a survey of 235 transplant centers, 4 the risk factors for PTLD in the first year after transplant included: (1) unrelated or HLA-mismatched donors (relative risk (RR) ¼ 4.1), (2) T-cell depletion (RR ¼ 12.7) and (3) the use of antithymocyte globulin (ATG) (RR ¼ 6.4) or anti-CD3 monoclonal antibodies (RR ¼ 43.2) for the prophylaxis or treatment of graft rejection and/or graft-versus-host disease (GVHD). PTLD occurred in 8% of HSCT recipients with two risk factors and 22% of recipients with three risk factors. For patients more than 1 year after HSCT, the only factor associated with PTLD was chronic GVHD (RR ¼ 4).
Consistent with the essential role of T cells in controlling the proliferation of latent EBV-infected B-cells, each of these risk factors is associated with prolonged and severe T-cell immunodeficiency. In fact, methods of T-cell depletion that selectively target T cell or T-and NK-cell populations confer a significantly higher risk of PTLD than methods that deplete both T-and B cells. 4, 11, 12 For example, in a study of over 2500 allogeneic transplants, the use of Campath-1 antibodies (that deplete both T-and B cells) for in vitro or in vivo T-cell depletion was associated with PTLD in only 1.3% of recipients. 11 Similarly, Barker et al. 13 reported a low rate (o2%) of PTLD among umbilical cord blood transplant recipients, perhaps resulting from the unique lymphocyte complement in cord blood allografts.
PCR assays for the preemptive diagnosis of PTLD Significant attention has been focused on assays for the early diagnosis of PTLD for two reasons. First, the clinical presentation can be nonspecific and easily confused with infection or GVHD. 2, 3 Second, it is a reasonable assumption that early treatment improves survival, although this has not been formally assessed in the rituximab era. Nearly all of the currently used assays for the preemptive (i.e., prior to clinical presentation) diagnosis of PTLD are based on PCR amplification of EBV DNA from the peripheral blood. An excellent review of assay methods used in solid organ transplant and HSCT recipients was recently published. 14 We will focus solely on PCR assays evaluated in HSCT recipients, as the pathogenesis, timing and course of PTLD differ significantly between these patients and solid-organ transplant recipients. 2, 15 Sensitive PCR assays can detect low levels of circulating EBV in many healthy individuals, limiting the predictive ability of qualitative assays. Thus, quantitative assays have been developed based on the supposition that the growth of EBV-infected B cells will correlate with an increase in peripheral blood EBV DNA. Initially, these methods were semiquantitative and required the comparison of Southern blot or agarose gel signals with calibrated controls. 5, [16] [17] [18] [19] Semiquantitative assays are generally imprecise and were superseded at many centers by quantitative PCRs based on co-amplification of EBV DNA and an internal calibration standard. The internal standard normalizes each reaction and overcomes the effect of PCR inhibitors (e.g. heparin) and the DNA isolation method.
14 More recently, real-time PCR assays (e.g. Taqman) have been developed that obviate the need for extensive handling of amplified specimens. These assays measure the fluorescence of amplified DNA products in a closed-tube system, allowing for simple, high-throughput analysis. Based on these advantages, real-time PCR assays have become the standard at most transplant centers and commercial laboratories.
Potential shortcomings of the preemptive PCR approach
The use of peripheral blood PCR to preemptively diagnose PTLD relies on the same paradigm that has been successfully applied to cytomegalovirus (CMV). In HSCT recipients, a sharp increase in the plasma viral load of CMV is an early and accurate predictor of the onset of clinically apparent CMV infection. 20 However, there are significant differences between the pathogenesis of PTLD and CMV infection that indicate this paradigm may not apply to EBV. Most notably, CMV infection results from active viral replication, while all EBV-positive malignancies are primarily associated with latent virus. Thus, the shedding of infectious virions into the blood is a major component of CMV disease, but does not play a significant role in PTLD. 2, 14, 15 Type III latency (the same found in lymphoblastoid B-cell lines) predominates in most PTLD, although multiple latency patterns may be present within a single lesion with lytic replication in a fraction of cells.
14 This heterogeneity is likely to further complicate quantitative PCR approaches.
A comparison of published studies that utilized PCR for the diagnosis of PTLD in HSCT recipients is included in Table 1 . 5, [7] [8] [9] [10] [21] [22] [23] [24] [25] [26] [27] [28] The number of unpublished, 'homebrewed' assays used at HSCT centers is unknown. The published assays vary markedly and have several potential shortcomings:
The study populations are exclusively derived from single centers and vary in the numbers of high-and low-risk patients, the methods of in vivo and in vitro T-cell depletion, the conditioning regimens and the use of antiviral prophylaxis. In some studies, patients with elevated viral loads may have had their immunosuppression tapered or stopped or received preemptive treatment for PTLD with antivirals, rituximab or lymphocytes. The PCR assays target different loci in the EBV genome, some of which (e.g. BamHI-W) are present in variable copy numbers. 29 Direct comparisons between PCR assays that target different loci are lacking. The amplification techniques (e.g. semiquantitative, realtime, nested) differ between studies. The frequency of PCR monitoring differed between studies. Since the doubling time of EBV VL can be as short as 46-56 h, 30, 31 PCR monitoring should be performed at least weekly to maximize the detection of an elevated VL prior to the clinical presentation of PTLD. The peripheral blood component(s) (i.e., peripheral blood mononuclear cells (PBMCs), whole blood or plasma) used for PCR differed between studies. This point is especially confounding, as the exact mechanism for viral shedding into the plasma remains unclear. Quantification of plasma viral load has the advantage of being relatively fast and simple. In addition, patients with lymphopenia may have insufficient cell numbers for reliable quantification of viral load in PBMCs. On the other hand, malignant cells may be lysed during the preparation of plasma DNA, leading to an artefactual elevation in the PCR assay. Although the mean EBV load in the peripheral blood appears to be higher among HSCT recipients with PTLD than in those without PTLD, patients with PTLD consistently present with PCR values that range over 1-5 logs (Table 1) . Furthermore, these values overlap significantly with PCR values from patients who did not develop PTLD. 9, 12, 28, 32 Finally, the threshold PCR values used to define patients at risk for PTLD were established by retrospectively analyzing single-institution experiences and have, for Table 1 A comparison of published studies using polymerase chain reaction (PCR) for measuring Epstein-Barr viral load in the peripheral blood of HSCT recipients, either prior to the clinical presentation of PTLD (above) or at the time of presentation (below)
Reference
Study patients PCR assay PTLD cases 
The Memorial Sloan-Kettering Cancer Center experience
A recent analysis of phase II chemotherapy trials, most of which were single-center, demonstrated an average reduction in response rate of 12.9% when the same regimens were evaluated in multicenter, phase III trials. 33 A combination of publication bias, patient selection and differences in clinical practice between institutions probably explain much of the disparity. Thus, it seems reasonable to expect a comparable decrement in performance for PCR assays when applied at other centers. Since 2003, the EBV assay used to monitor HSCT recipients at Memorial SloanKettering Cancer Center (MSKCC) is a real-time PCR of the BNRF1-p143 locus (Roche, Inc.). 34 Between May /2003 and May 2005, 118 patients underwent an initial, T-celldepleted allogeneic HSCT at MSKCC. Of the 118, 112 had EBV PCR performed at least once. Thirty-five (31.3%) had detectable DNA on at least one occasion, including 28 (25.0%) who had viral loads above the previously defined threshold of 1000 gEq/ml. 9, 35 Five (4.2%) of the 118 patients developed PTLD after HSCT ( Table 2 ). All five had elevated PCR values (i.e., 41,000 gEq/ml) at the time of clinical presentation, but only three of the five had elevated PCR values within 28 days prior to diagnosis. These five patients with PTLD did not differ from the 23 patients who had elevated PCR but did not develop PTLD with respect to the use of ATG (P ¼ 0.27) or a mismatched or unrelated donor (P ¼ 0.74). PTLD presented between 55 and 680 days after HSCT, and was treated with rituximab, donor leukocyte infusion (DLI) and/or EBV-specific cytotoxic T lymphocytes (CTL) ( Table 2 ). Only patient #1 died from PTLD and overall survival among patients with PTLD did not differ from patients without PTLD (P ¼ 0.97). Thus, our experience was similar to several reports in the literature. The sensitivity of the PCR assay was better for diagnosing patients who presented with a syndrome consistent with PTLD than for preemptive diagnosis, and demographic factors did not clearly delineate an at-risk population. The poor sensitivity and positive predictive value of the BNRF1-p143 PCR have prompted us to reevaluate the use of this assay. We expect that similar reports from other institutions will be forthcoming. Based on our results, the number of patients who needed to receive preemptive rituximab (assuming 100% efficacy) in order to prevent a single case of PTLD was 5.6. No randomized data are currently available to guide practitioners on the correct number of patients that it is appropriate to treat in order to potentially prevent one case.
Studies outlining preemptive treatment based on PCR screening
A limited number of studies have described the preemptive treatment of HSCT recipients with elevated EBV loads ( Table 3) . Van Esser et al. 35 monitored 49 recipients of T-cell-depleted allografts weekly using the plasma BNRF1-p143 PCR. Seventeen patients developed an elevated EBV VL (i.e., 41000 gEq/ml). Two of the 17 presented with concurrent PTLD, and the remaining 15 were treated preemptively with a single dose of rituximab 375 mg/m 2 . Fourteen (93%) patients had complete resolution of their elevated VL. The one remaining patient progressed to PTLD but was cured with DLI and additional rituximab. The overall incidence of PTLD in patients with EBV reactivation after receiving T-cell-depleted allografts was reduced from 49%, in a high-risk historical cohort, to 18% in the patients who received single-dose, preemptive rituximab, and the attributable mortality from PTLD was reduced from 26 to 0%.
Using the same PCR assay, Dominietto et al. 22 reported an elevated EBV PCR in 19% of HSCT recipients given 1-2 antigen mismatched related or unrelated allografts, all of who received ATG. Transplant-related mortality among patients with EBV reactivation was 40%, compared to 21% among patients without EBV reactivation. Preemptive rituximab was given to 11 patients with elevated viral loads. One of the 11 subsequently developed PTLD, as did one patient who presented with a PCR viral load o1,000 gEq/ ml. Four additional studies have described patients with elevated viral loads who were treated with preemptive donor leukocytes, CTLs and/or rituximab. 17, [36] [37] [38] The small number of patients in these studies and the absence of a randomized comparison preclude any definitive statement about the efficacy of PCR screening and preemptive rituximab. Nevertheless, preemptive rituximab is becoming a common approach at some transplant centers. 12, 35, 39 The cost-effectiveness of preemptive rituximab and its effects on immune reconstitution and survival remain unknown. Most importantly, there is no clear evidence that preemptive diagnosis and early treatment is superior to prompt treatment of patients presenting with PTLD. In a report by Wagner et al. 10 of 1300 PCR samples from 85 patients, eight patients developed PTLD and were successfully treated with rituximab and/or CTLs. In another study, Cesaro et al. 7 tapered immunosuppression in 28 alloSCT recipients with PCR-detected, EBV reactivation. PTLD developed in only one patient and was successfully treated.
At least two studies indicate that the prophylactic infusion of EBV-specific CTLs is a feasible option for patients at high risk for developing PTLD. Rooney et al. 41 administered prophylactic EBV-specific CTLs to 36 patients after T-cell-depleted HSCT from mismatched related or matched unrelated donors. None of the patients who received prophylactic CTLs developed PTLD, compared to 14% of 52 untreated patients. In addition, the CTLs persisted for up to 2 years. The prophylactic use of CTLs has not been formally compared with prophylactic or preemptive rituximab in regards to efficacy, cost-effectiveness or toxicity.
Future directions and unanswered questions
Despite the lack of randomized trials to support preemptive treatment based on PCR testing, at least one center has argued that preemptive rituximab is so efficacious that it is 'ethically difficult' to do otherwise, 12 and several centers now routinely use this approach. Before the utility of PCR assays and preemptive rituximab are accepted as axiomatic, we believe that randomized trials must be performed. Further indication that PCR-directed therapy has become a standard approach is BMT CTN Protocol 0303 (http:// spitfire.emmes.com/study/bmt/protocol/0303_protocol/ 0303_protocol.html), a multicenter trial of HLA-matched, T-cell-depleted HSCT for patients with AML in first or second remission. Patients with an elevated viral load using the BNRF1-p143 PCR will receive a single dose of rituximab 375 mg/m 2 . If the viral load fails to normalize, the patients will be treated with three additional doses of rituximab. To avoid institution-specific differences in DNA isolation and PCR amplification, all assays are being performed at a single center. The effects of rituximab on viral load, development of PTLD and B-cell subsets will be assessed prospectively. This study will provide some useful outcomes data and correlative information on immune reconstitution, but it does not include a comparison arm (e.g., prompt treatment of clinically apparent PTLD 10 ). Thus, the benefit of preemptive diagnosis and rituximab on overall survival will not be evaluable.
It is important to recognize that PTLDs are highly heterogeneous and differ markedly in pathogenesis from infections such as CMV. Thus, whether a patient's PCR value simply exceeds a predetermined cutoff value is unlikely to be the optimal predictor of that patient's risk of developing PTLD. Further clinical and laboratory studies are needed to identify patient-specific correlates that affect the risk of developing PTLD. Thus far, singleinstitution studies have failed to identify clinical factors that predict whether a patient with EBV reactivation detected by PCR will or will not proceed to clinically apparent PTLD.
Potential risk factors such as the prior reactivation of a herpesvirus (e.g. CMV, HHV-6) or the use of newer agents to treat GVHD (e.g. daclizumab, pentostatin) have not been evaluated in large studies. Sirvent-von Bueltzingsloewen et al. 28 reported that a rapid increase in viral burden was a better predictor of disease onset than simply exceeding an absolute PCR threshold. Other groups have not clearly corroborated this experience, 9, 24 but the rate of rise has not been adequately evaluated as a potential harbinger of PTLD. Considering the small numbers of patients at each center, a meta-analysis of all available data on preemptive monitoring may be quite useful.
Several groups have reported laboratory-based methods (e.g. EBV gene expression, EBV-specific T-cell responses) that could eventually be used to identify patients at high risk for developing PTLD. 15, [42] [43] [44] A correlation between impaired recovery of EBV-specific cellular immunity after HSCT and an increased risk of EBV reactivation and PTLD has been demonstrated using HLA tetramers specific for lytic and latent EBV antigens. 43, 44 In a study by Meij et al., 44 the positive predictive value of the PCR improved from 40%, among all patients with EBV reactivation, to 100% among a subset lacking detectable EBV-specific CD8 þ T cells. Further development of correlative studies is needed to improve the diagnostic ability of HSCT practitioners, who currently must rely on assays that cannot clearly distinguish patients with reactivation who will and will not progress to PTLD.
Several questions remain unanswered (Figure 1 ). Fundamental research and randomized studies are needed to determine the answers to these questions and optimize the diagnosis and treatment of this life-threatening disorder.
What is the source of EBV DNA in the plasma? What is the relationship between PTLD histology and peripheral blood viral load? What are the effects of patient-based risk factors (e.g. age, conditioning regimen, immunosuppression, stem cell source and quantity, underlying disease) on viral load? What are the correlative laboratory studies that will improve the predictive value of the EBV PCR? What is an acceptable number of patients needed to treat with preemptive therapy to prevent a single case of PTLD? Do preemptive treatments (e.g. rituximab, CTLs) improve overall survival compared to promptly treating patients with clinically apparent PTLD? Figure 1 Unanswered questions about PTLD diagnosis and treatment.
